The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox

Abstract

Recently, the role of receptor activator of nuclear factor kappa B, receptor activator of nuclear factor kappa B ligand, and the osteoprotegerin system has been recognized as more important in the pathogenesis of cardiovascular disease. No consensus is yet available on the function of osteoprotegerin, but all these studies have concluded that osteoprotegerin is a promising biomarker for coronary artery disease, regardless of whether it plays a protective role against atherosclerosis or causes atherosclerosis with its proatherogenic features. Cardiovascular disease is one of the most frequent causes of mortality and morbidity worldwide. Several variables have been identified as risk factors for cardiovascular disease. Recently, the role of receptor activator of nuclear factor kappa B, receptor activator of nuclear factor kappa B ligand, and the osteoprotegerin system has been recognized as more important in the pathogenesis of cardiovascular disease. Besides their roles in the regulation of bone resorption, these molecules have been reported to be associated with the pathophysiology of cardiovascular disease. There are conflicting data regarding the impact of osteoprotegerin, a glycoprotein with a regulatory role in the cardiovascular system. The aim of this review is to discuss the current knowledge and the role of osteoprotegerin in cardiovascular disease.

Keywords

• Cardiovascular disease, heart, inflammatory markers, osteoprotegerin

Kaynakça

1. 1. Lopez ADM, CD, Ezzati M, Jamison DT, Murray CJ. Global Burden of Disease and Risk Factors: Disease Control Priorities Project. New York, NY: World Bank and Oxford University Press; 2006.
2. 2. Yeboah J, Erbel R, Delaney JC, Nance R, Guo M, Bertoni AG, et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: the MultiEthnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis 2014;236:411-7.
3. 3. Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004;25:401-8.
4. 4. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
5. 5. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53.
6. 6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
7. 7. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
8. 8. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.

9. 9. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O’Brein T, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001;280:334-9.
10. 10. Malyankar UM, Scantena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000;275:20959-62.
11. 11. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849- 54.
12. 12. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Haran K, et al. Serum osteoprotegerin levels are associated with presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
13. 13. Uyama O, Yoshimoto Y, Yamamoto Y, Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 1997;28:1730-2.
14. 14. Browner WS, Lul LY, Cumming SR. Association of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clinic Endocrinol Metab 2001;86:631-7.
15. 15. Ueland T, Yndestad A, Oie E, Florhormen G,Halvorsen B, Frøland SS, et al. Dysregulated osteoprotegerin/ RANK ligand/ RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-8.
16. 16. Xi L, Cao H, Zhu J, Roe OD, Li M, Wu Y, et al. OPG/RANK/RANKL axis in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients after mitral valve surgery. Cardiology 2013;124:18-24.
17. 17. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) 2001;79:243- 53.
18. 18. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998;273:5117-23.
19. 19. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, et al. OPG/ FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is upregulated by ligating CD40. J Immunol 1998;161:6113-21.